Navigation Links
T-cell therapy eradicates an aggressive leukemia in 2 children
Date:3/25/2013

n, is co-first author on the study.

The current study builds on Grupp's ongoing collaboration with Penn Medicine scientists who originally developed the modified T cells as a treatment for B-cell leukemias. The Penn team reported on early successful results of a trial using this cell therapy in three adult chronic lymphocytic leukemia (CLL) patients in August of 2011. Two of those patients remain in remission more than 2 years following their treatment, and as the Penn researchers reported in December 2012 at the annual meeting of the American Society of Hematology, seven out of ten adult patients treated at that point responded to the therapy. The team is led by the current study's senior author, Carl H. June, M.D., the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and the Perelman School of Medicine at the University of Pennsylvania and director of Translational Research in Penn's Abramson Cancer Center.

"We're hopeful that our efforts to treat patients with these personalized cellular therapies will reduce or even replace the need for bone marrow transplants, which carry a high mortality risk and require long hospitalizations," June said. "In the long run, if the treatment is effective in these late-stage patients, we would like to explore using it up front, and perhaps arrive at a point where leukemia can be treated without chemotherapy."

The research team colleagues adapted the original CLL treatment to combat another B-cell leukemia: ALL, which is the most common childhood cancer. After decades of research, oncologists can currently cure 85 percent of children with ALL. Both children in the current study had a high-risk type of ALL that stubbornly resists conventional treatments.

The new study used a relatively new approach in cancer treatment: immunotherapy, which manipulates the immune system to increase its cancer-fighting capabilities. Here the researchers engineered
'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia

Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
Perelman School of Medicine, University of Pennsylvania


Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Infusion of stem cells and specially generated T-cells from same donor improves leukemia survival
2. Denosumab reduces burden of giant-cell tumor of the bone
3. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
4. UCLA, Caltech research on immune-cell therapy could strengthen promising melanoma treatment
5. Physical therapy as effective as surgery for torn meniscus and arthritis of the knee
6. PREFERRED Therapy Providers Selects WebOutcomes to Deliver Web-Based Outcomes for Their National Provider Network
7. Gene Therapy for Human Disease: Clinical Advances and Challenges
8. Immune Therapy Shows Early Promise for Advanced Leukemia
9. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
10. Therapy as Good as Surgery for Some With Torn Knee Cartilage
11. Women's Excellence in Pelvic Floor Physical Therapy Near Pontiac, MI, Now Offers Therapy After Vaginal Delivery to Prevent Urinary Incontinence, Improve Sexual Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... December 25, 2014 BambooFlooringChina.com sells many ... quality bamboo flooring. Today, the company announces big ... many styles and colors. , BambooFlooringChina.com is the world’s ... the promotion is valid until Jan. 20, 2015. , ... and woven with a natural thread. All the bamboo ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide ... Now, all of the models at LunaDress.co.uk come with big discounts, ... the wedding veil can turn out to be a most exciting ... veil can always bring surprise to a wedding. On the updated ... choose veils for a big day . , Going out ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... controlled, multi-center trial has found that cardiac resynchronization ... during exercise testing, the trial,s primary endpoint, in ... problems that disrupt the heart,s normal rhythm and ... EKG. , The Resynchronization Therapy in Narrow QRS ...
... 6 ,PharmAthene, Inc. (Amex: PIP ), a ... threats, and Medarex, Inc.,(Nasdaq: MEDX ), a ... 2008 Department of Defense (DoD) appropriations bill includes ... basis to support,ongoing development of Valortim(TM), a fully ...
... Neurotech Pharmaceuticals, Inc.,a biotechnology company focused on ... diseases, announced today the completion,of enrollment of ... evaluating,NT-501, the Company,s lead product, for the ... (RP) and the dry form of age-related,macular ...
... ROCKVILLE, Md., Nov. 6 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,reported ... September 30,2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) ... approximately $3,520,000,versus $3,023,000 for the comparable period a ...
... ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. ... announced that Cameron Groome, Executive,Vice-President, Corporate & Strategic ... Annual Global Healthcare Conference in New York City,tomorrow. ... Time) in the Holmes,II Room of the New ...
... WEBCAST TO FOLLOW, BIRMINGHAM, Ala., Nov. 6 ... its third quarter,2007 financial results will be released on ... will host a conference call and live,webcast. The call ... Chief,Executive Officer, and Stuart Grant, Senior Vice President and ...
Cached Medicine News:Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 2Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 3Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 4Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 5Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 6Health News:PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM) 7Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 2Health News:Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 2Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 3Health News:BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007 4
(Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
(Date:12/24/2014)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... unaudited preliminary financial results for the first quarter ... 2015 Ended September 30, 2014 Financial Highlights: ... million in 1Q14 with gross margins improved to ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... Uroplasty, Inc. (NASDAQ: UPI ) announced today ... of fiscal 2012 ended June 30, 2011, at the market ... a conference call to discuss these results on Thursday, July ... Time). David Kaysen, President and Chief Executive Officer, and Medi ...
... 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... 1 clinical study for ISIS-PTP1BRx, an antisense drug for ... phosphatase-1B, PTP-1B.  ISIS-PTP1BRx is designed to increase the body,s ... glucose control for patients with type 2 diabetes.  Because ...
Cached Medicine Technology:Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011 2Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes 2Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes 3Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: